PHILADELPHIA, April 18, 2015 /PRNewswire/ --
Aurigene and its partner Curis, Inc. (NASDAQ: CRIS) will be
presenting data at the poster sessions from two programs at the
American Associate of Cancer Research Annual Meeting (April 18-22 in Philadelphia, PA).
(Logo:
http://photos.prnewswire.com/prnh/20130418/608115)
Aurigene will present data for its proprietary Nicotinamide
phosphoribosyltransferase (NAMPT) small molecule inhibitors
program, which is currently in preclinical development.
Aurigene and Curis will present data from their interleukin-1
receptor association kinase-4, or IRAK-4, inhibitor program.
Additional information on the presentations can be found
below and abstracts can be accessed
at http://www.aacr.org.
Poster Presentations
NAMPT
Title: Discovery of dihydro-isoxazole derivatives as novel
inhibitors of NAMPT for the treatment of multiple
myeloma
Session Category: Experimental and Molecular Therapeutics
Session Title: Drug Discovery
Session Date and Time: Wednesday
April 22, 2015 8:00 AM - 12:00
PM
Abstract Number: 3647
IRAK4
Title: Novel IRAK-4 inhibitors exhibit highly potent
anti-proliferative activity in DLBCL cell lines with activating
MYD88 L265P mutation
Session Category: Chemistry
Session Title: Drug Discovery: Kinases, Nuclear Hormone
Receptors, and Novel Targets
Session Date and Time: Tuesday,
April 21, 2015, 8:00 AM - 12:00
PM
Abstract Number: 3646
About Aurigene
Aurigene is a specialized, discovery stage biotechnology
company, developing novel and best-in-class therapies to treat
cancer and inflammatory diseases. Aurigene's Programmed Death
pathway program is the first of several immune checkpoint programs
that are at different stages of discovery and preclinical
development. Aurigene has partnered with several large- and
mid-pharma companies in the United
States and Europe and has
delivered multiple clinical compounds through these partnerships.
With over 500 scientists, Aurigene has collaborated with 6 of the
top 10 pharma companies. For more information, please visit
Aurigene's website at http://aurigene.com/.
About Curis, Inc.
Curis is a biotechnology company focused on the development and
commercialization of innovative drug candidates for the treatment
of human cancers. Curis' pipeline of drug candidates includes
CUDC-907, a dual HDAC and PI3K inhibitor, CUDC-427, a small
molecule antagonist of IAP proteins, and CUDC-305, an oral HSP90
inhibitor. Curis is also engaged in a broad collaboration with
Aurigene in the areas of immuno-oncology and precision oncology. As
part of this collaboration, Curis expects to exercise options to
exclusively license oral small molecule antagonists of PD-L1 and
IRAK4 and file IND application for both molecules in 2015. Curis is
also party to a collaboration with Genentech, a member of the Roche
Group, under which Genentech and Roche are developing and
commercializing Erivedge® for the treatment of advanced basal cell
carcinoma. For more information, visit Curis' website at
http://www.curis.com
Media Contact:
Rajshree KT
Director Strategic Alliances
+91-40-4465 7777
SOURCE Aurigene